India Pharma's Digital Leap:
GoVal's Paperless Validation Success
The customer is one among the leading pharma companies India and ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central systema nervosum (CNS), gastro-intestinal (GI) and women healthcare (WHC).
[ FROM MANUAL TO DIGITAL ]
Addressing Key Validation Challenges
Our client, a leading pharmaceutical company, faced significant challenges with their manual validation processes. They sought a robust software solution to drive a digital transformation, moving away from error-prone manual Computer System Validation (CSV) to a streamlined paperless validation approach. Specifically, they aimed to:
- Eliminate manual errors during testing, ensuring data integrity and accuracy.
- Streamline review and approval processes, reducing bottlenecks and accelerating validation timelines.
- Reduce validation and approval process timelines, improving time-to-market.
- Improve operational efficiency across their validation lifecycle.
- Automate test protocol execution, deviation recording, traceability matrix generation and Validation Summary Report creation.
By implementing a comprehensive digital validation solution, they aimed to achieve enhanced GxP compliance and significantly improve their overall validation workflow.
[ RAPID TRANSFORMATION ]
GoVal's Accelerated Validation Solution
GoVal provides a comprehensive Validation Lifecycle Management System (VLMS) designed to transform your validation processes. Our solution empowers life science companies to move beyond traditional, paper-based workflows and embrace a fully digital approach.
Configuration & Validation Sprint
GoVal's platform was rapidly configured and validated, laying the foundation for a seamless digital transition.
Rapid Setup & UAT
We established CSV and Change Management processes on the platform and completed UAT, ensuring user readiness.
Live Implementation & Impact
In just 3 months, the GoVal solution was fully operational, with complete training and all validation artifacts delivered.
[ VALIDATION REIMAGINED ]
GoVal's Proven Business Advantages
- 100% Paperless Transformation: GoVal eliminated all paper records, ushering in a fully digital VLMS environment.
- Enhanced Risk & Compliance: FMEA-based risk assessments, GxP assessments aligned with SOPs, GAMP categorization.
- Deep Dive Test Analysis: In-depth analysis of test cases and results, with streamlined discrepancy management.
- Accelerated Testing: Parallel execution of test scripts, screen recording, and easy upload of instrument results and screenshots.
- Project & Task Mastery: Validation project plan generation, with integrated task allocation and follow-up.
- Centralized Document Control: Secure DMS for storing all generated PDF validation documents.
- Instant Team Synergy: Collaborate instantly. Multiple users work together in real time, streamlining validation and boosting team efficiency.
- Automated Reporting & Review: Automated Validation Summary Reports (VSR), system release certificates, and enabled periodic review processes.
- Real-Time Metrics: Improved metrics on all process aspects, including a real-time validation status dashboard.
- Audit Readiness: Significantly improved audit preparedness.
Frequently Asked Questions
Everything you need to know about paperless GxP validation with GoVal.
GoVal eliminates the root causes of paper-based audit findings: missing signatures, illegible entries, backdated records, and untraceable changes. From go-live, every validation action generates a tamper-evident, timestamped audit trail that satisfies FDA 21 CFR Part 11 and EU Annex 11 out of the box. Customers who switched after receiving 483 observations have used GoVal to prepare remediation packages for re-inspection within one quarter.
The direct cost of paper-based validation includes storage, printing, courier fees, and the staff time consumed by manual transcription, routing, and retrieval. But the larger exposure is regulatory: a single FDA warning letter or consent decree can cost tens of millions in remediation, lost revenue, and reputational damage. GoVal customers routinely quantify the ROI as validation cycle time savings alone — Alembic Pharma recovered 1,955 validation days per year, which represents a measurable return that justifies platform investment within months.
No. Switching to GoVal for new validation projects does not trigger revalidation of your existing validated systems. Your legacy paper records remain as your compliance evidence for those systems. GoVal is introduced under your change control SOP as a new validated computer system — GoVal provides the IQ/OQ documentation for its own platform — and from that point, all new and periodic review activities run digitally. A phased approach is standard and fully defensible.
Yes. A single GoVal instance supports unlimited sites and geographies from one admin console. Each site has its own workspace, local user permissions, and site-specific protocol templates, while corporate QA sees a unified compliance dashboard across the entire organisation. Multi-language support and regional regulatory configurations (FDA, EMA, CDSCO) are managed within the same platform.
GoVal operates on a 99.9% SLA with automated failover and geo-redundant backups. All your validation records are exportable in PDF and structured data formats at any time — you are never locked in. If you choose to migrate to a different system in the future, GoVal provides a full data export package that maintains regulatory integrity. You own your data; GoVal hosts it.
Every GoVal customer is assigned a dedicated Customer Success Manager who has a background in pharmaceutical QA or validation — not generic SaaS support. Your CSM understands the difference between a URS and a VSR, can read your SOPs, and proactively flags when platform updates have regulatory implications for your workflows. This domain expertise is the reason GoVal customers renew at the rate they do.